4.5 Article

Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice

Journal

NEUROBIOLOGY OF AGING
Volume 22, Issue 6, Pages 1007-1012

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0197-4580(01)00292-5

Keywords

lipopolysaccharide; beta-amyloid; MHC-II; microglia; Alzheimer's disease

Funding

  1. NIA NIH HHS [AG 18478, AG 15490] Funding Source: Medline

Ask authors/readers for more resources

Multiple lines of evidence indicate that inflammatory processes are involved in the pathogenesis of Alzheimer's disease. Lipopolysaccharide (LPS) is widely used to induce inflammation in experimental systems. Consequently we injected LPS or saline intrahippocampally in 11 and 16 months old APP + PS1 transgenic mice to induce brain inflammation, then used immunocytochemistry to examine amyloid pathology 7 days later. As expected, LPS activated microglia as indicated by a significant increase in the area covered by major histocompatibility complex-II (MHC-II) immunostaining in the mice injected with LPS compared to the saline injected. Simultaneously, A beta immunostaining showed an unexpected reduction of the A beta load in the mice injected with LPS compared to the saline injected. This effect of LPS on the A beta load in APP+PS1 mice strengthens the hypothesis that moderate amounts of microglial activation may be beneficial in Alzheimer's disease, by increasing the clearance of A beta. (C) 2001 Elsevier Science Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available